Qx. Li et al., PROTEOLYTIC PROCESSING OF ALZHEIMERS-DISEASE BETA-A4 AMYLOID PRECURSOR PROTEIN IN HUMAN PLATELETS, The Journal of biological chemistry, 270(23), 1995, pp. 14140-14147
The processing of amyloid precursor protein (APP) and production of be
ta A4 amyloid are events likely to influence the development and progr
ession of Alzheimer's disease, since beta A4 is the major constituent
of amyloid deposited in this disorder. Our previous studies showed tha
t human platelets contain full-length APP (APP(FL)) and are a suitable
substrate to study normal APP processing, In the present study, we sh
ow that a 22-kDa beta A4-containing carboxyl-terminal fragment (22-CTF
) of APP is present in unstimulated platelets. Both APP(FL) and 22-CTF
are proteolytically degraded when platelets are activated with thromb
in, collagen, or calcium ionophore A23187. Complete cleavage of APP(FL
) and 22-CTF require the presence of extracellular calcium, Following
stimulation in the presence of calcium, a new CTF of 17 kDa is generat
ed, and the NH2-terminal epitope of beta A4 amyloid is lost. Preincuba
tion of platelets with the cell-permeable cysteine protease inhibitors
calpeptin, -trans-epoxysuccinyl-L-leucyl-amido-3-methylbutane ethyl e
ster (E64d), Na-alpha-p-tosyl-L-lysine chloromethyl ketone, or calcium
chelator EGTA before platelet stimulation inhibits the degradation of
both APP(FL) and 22-CTF. Divalent metal ions including zinc, copper,
and cobalt inhibit the degradation of APP(FL) and 22-CTF. This study s
uggests that a calcium-dependent neutral cysteine protease is involved
in the proteolytic processing of an amyloidogenic species of APP in h
uman platelets.